Search
Close this search box.
Search

Oncology

Foundation One

Foundation One is a genetic test capable of precisely identifying all cells and genes in the genetic profile of patients with solid tumors. Based on its results, physicians gain access to more accurate information, enabling them to adopt a personalized treatment approach for the patient.

Overview

Cancer cases worldwide are expected to increase by 77% by 2050

Lung cancer was the most diagnosed cancer globally in 2022, with nearly 2.5 million new cases and over 1.8 million deaths.

Non-melanoma skin cancer is the most frequent cancer in Brazil, accounting for approximately 30% of all malignant tumors registered in the country.

When Should You Consider This Test?

Consider this test in the following cases:

Patients with advanced or metastatic cancer, seeking targeted therapies.;
Patients with rare tumors, lacking standard treatment options.;
Patients who did not respond well to conventional treatments.

Genes Analyzed

Foundation One examines over 300 cancer-related genes, varying according to the test version (such as FoundationOne CDx, FoundationOne Liquid, etc.). Frequently analyzed genes include:

  • BRCA1/BRCA2 (related to breast and ovarian cancer).
  • TP53 (common in various cancer types).
  • EGFR, KRAS, ALK, BRAF (often associated with lung cancer and other types).
  • PIK3CA, PTEN (related to solid tumors).

Methodology

The methodology used for this test is as follows:

PREPARATION:

Biopsy: Paraffin Block or Slide

TURNAROUND TIME:

Up to 25 calendar days

REQUIRED DOCUMENTS:

Medical request, pathology report

Sample:

Biopsy
Type Description
Technique NGS + CNVs
Accuracy 99%

How to Request the Test?

Contact Our Customer Services
Exatus Gene will send a collection kit and provide instructions for sample collection.
We will retrieve the collected sample and send it to the laboratory for analysis.
The report will be made available through the SysGene Portal and sent to your email.